UB Paderborn / Katalog / Suche / in CDI

1 – 21 von 21

Sortiert nach

Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas

The Journal of clinical investigation, 2017-04, Vol.127 (4), p.1425-1437

2017

Volltextzugriff (PDF)

Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy

Frontiers in immunology, 2019-01, Vol.9, p.3062-3062

2019

Volltextzugriff (PDF)

Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy

The Journal of experimental medicine, 2018-01, Vol.215 (1), p.141-157

2018

Volltextzugriff (PDF)

Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma

Journal for immunotherapy of cancer, 2021-06, Vol.9 (6), p.e002181

2021

Volltextzugriff (PDF)

Novel EGFRvIII-CAR transgenic mice for rigorous preclinical studies in syngeneic mice

Neuro-oncology (Charlottesville, Va.), 2022-02, Vol.24 (2), p.259-272

2022

Volltextzugriff (PDF)

Considerations when treating high-grade pediatric glioma patients with immunotherapy

Expert review of neurotherapeutics, 2021-02, Vol.21 (2), p.205-219

2021

Volltextzugriff (PDF)

Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma

Journal for immunotherapy of cancer, 2022-05, Vol.10 (5), p.e004644

2022

Volltextzugriff (PDF)

IMMU-28. INDUCTION OF TERTIARY LYMPHOID STRUCTURE-LIKE T-CELL CLUSTERS BY DELIVERY OF A NOVEL GENE COMBINATION INTO AN IMMUNOCOMPETENT MOUSE MODEL OF GLIOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2020-11, Vol.22 (Supplement_2), p.ii110-ii111

2020

Volltextzugriff (PDF)

Abstract 74: Engineering tertiary lymphoid structures for glioblastoma: A novel gene combination promotes therapeutic TLS formation in an immune-competent mouse model of GBM

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.74-74

2021

Volltextzugriff (PDF)

Pilot Implementation of a Multidisciplinary Tumor Board Seminar Series to Foster Increased Understanding of and Interest in Oncologic Care Among Medical Students

International journal of radiation oncology, biology, physics, 2022-09, Vol.114 (1), p.e15-e16

2022

Volltextzugriff (PDF)

EXTH-15. INHIBITION OF 2-HG LEADS TO UPREGULATION OF A PRO-INFLAMMATORY GENE SIGNATURE IN A NOVEL HLA-A2/HLA-DR1 TRANSGENIC MOUSE MODEL OF IDH1R132H-EXPRESSING GLIOMA

Neuro-oncology (Charlottesville, Va.), 2020-11, Vol.22 (Supplement_2), p.ii89-ii90

2020

Volltextzugriff (PDF)

IMMU-57. SEQUENTIAL TWO-RECEPTOR PRIMING CAR SYSTEM TO OVERCOME HETEROGENEOUS ANTIGEN EXPRESSION

Neuro-oncology (Charlottesville, Va.), 2018-11, Vol.20 (suppl_6), p.vi134-vi134

2018

Volltextzugriff (PDF)

IMMU-21. SEQUENTIAL TWO-RECEPTOR PRIMING CAR SYSTEM TO OVERCOME HETEROGENEOUS ANTIGEN EXPRESSION

Neuro-oncology (Charlottesville, Va.), 2019-11, Vol.21 (Supplement_6), p.vi123-vi123

2019

Volltextzugriff (PDF)

IMMU-33. MULTI-ANTIGEN RECOGNITION CIRCUITS OVERCOME CHALLENGES OF SPECIFICITY, HETEROGENEITY, AND DURABILITY IN T-CELL THERAPY FOR GLIOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2020-11, Vol.22 (Supplement_2), p.ii111-ii112

2020

Volltextzugriff (PDF)

IMMU-42. ONO-AE3-208 PROMOTES ANTI-TUMOR IMMUNE ACTIVITY AND SURVIVAL IN GLIOMA MODELS

Neuro-oncology (Charlottesville, Va.), 2017-11, Vol.19 (suppl_6), p.vi122-vi122

2017

Volltextzugriff (PDF)

Abstract 3767: Identification of a novel and a shared H3.3K27M mutation derived neoantigen epitope and H3.3K27M specific TCR engineered T cell therapy for glioma

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.3767-3767

2017

Volltextzugriff (PDF)

Isocitrate dehydrogenase mutations suppress STAT1 and CD8 super( +) T cell accumulation in gliomas

The Journal of clinical investigation, 2017-04, Vol.127 (4), p.1425-1425

2017

Volltextzugriff (PDF)

Isocitrate dehydrogenase mutations suppress STAT1 and CD8^sup +^ T cell accumulation in gliomas

The Journal of clinical investigation, 2017-04, Vol.127 (4), p.1425

2017

Volltextzugriff (PDF)

Isocitrate dehydrogenase mutations suppress STAT1 and [CD8.sup.+] T cell accumulation in gliomas

The Journal of clinical investigation, 2017-04, Vol.127 (4), p.1425

2017

Volltextzugriff (PDF)

IMMU-41. H3.3K27M MUTATION-DERIVED NOVEL NEOANTIGEN – CHARACTERIZATION OF THE HLA-A2-BINDING EPITOPE AND A SPECIFIC T CELL RECEPTOR FOR DEVELOPMENT OF T CELL-BASED IMMUNOTHERAPY

Neuro-oncology (Charlottesville, Va.), 2017-11, Vol.19 (suppl_6), p.vi121-vi121

2017

Volltextzugriff (PDF)

Chapter 59 - Immunotherapy Response Assessment in Neuro-Oncology (iRANO)

Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy, 2018, p.761-766

Second Edition, 2018

Volltextzugriff (PDF)

1 – 21 von 21

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20)
Mit Volltextzugriff
(18)

Publikationsform

Artikel
(20)
Buchkapitel
(1)

Sprache

Englisch
(21)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas

Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy

Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy

Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma

Novel EGFRvIII-CAR transgenic mice for rigorous preclinical studies in syngeneic mice

Considerations when treating high-grade pediatric glioma patients with immunotherapy

Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma

IMMU-28. INDUCTION OF TERTIARY LYMPHOID STRUCTURE-LIKE T-CELL CLUSTERS BY DELIVERY OF A NOVEL GENE COMBINATION INTO AN IMMUNOCOMPETENT MOUSE MODEL OF GLIOBLASTOMA

Abstract 74: Engineering tertiary lymphoid structures for glioblastoma: A novel gene combination promotes therapeutic TLS formation in an immune-competent mouse model of GBM

Pilot Implementation of a Multidisciplinary Tumor Board Seminar Series to Foster Increased Understanding of and Interest in Oncologic Care Among Medical Students

EXTH-15. INHIBITION OF 2-HG LEADS TO UPREGULATION OF A PRO-INFLAMMATORY GENE SIGNATURE IN A NOVEL HLA-A2/HLA-DR1 TRANSGENIC MOUSE MODEL OF IDH1R132H-EXPRESSING GLIOMA

IMMU-57. SEQUENTIAL TWO-RECEPTOR PRIMING CAR SYSTEM TO OVERCOME HETEROGENEOUS ANTIGEN EXPRESSION

IMMU-21. SEQUENTIAL TWO-RECEPTOR PRIMING CAR SYSTEM TO OVERCOME HETEROGENEOUS ANTIGEN EXPRESSION

IMMU-33. MULTI-ANTIGEN RECOGNITION CIRCUITS OVERCOME CHALLENGES OF SPECIFICITY, HETEROGENEITY, AND DURABILITY IN T-CELL THERAPY FOR GLIOBLASTOMA

IMMU-42. ONO-AE3-208 PROMOTES ANTI-TUMOR IMMUNE ACTIVITY AND SURVIVAL IN GLIOMA MODELS

Abstract 3767: Identification of a novel and a shared H3.3K27M mutation derived neoantigen epitope and H3.3K27M specific TCR engineered T cell therapy for glioma

Isocitrate dehydrogenase mutations suppress STAT1 and CD8 super( +) T cell accumulation in gliomas

Isocitrate dehydrogenase mutations suppress STAT1 and CD8^sup +^ T cell accumulation in gliomas

Isocitrate dehydrogenase mutations suppress STAT1 and [CD8.sup.+] T cell accumulation in gliomas

IMMU-41. H3.3K27M MUTATION-DERIVED NOVEL NEOANTIGEN – CHARACTERIZATION OF THE HLA-A2-BINDING EPITOPE AND A SPECIFIC T CELL RECEPTOR FOR DEVELOPMENT OF T CELL-BASED IMMUNOTHERAPY

Chapter 59 - Immunotherapy Response Assessment in Neuro-Oncology (iRANO)

Suchergebnisse filtern